Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 11 of 11 publications.

Trickey A, Nixon E, Christensen H, Finn A, Thomas A, Relton C, Montgomery C, Hemani G, Metz J, Walker JG, Turner K, Kwiatkowska R, Sauchelli S, Danon L, Brooks-Pollock E. University students and staff able to maintain low daily contact numbers during various COVID-19 guideline periods. Epidemiol Infect. 2021 Aug 10;149:e169. doi: 10.1017/S0950268821001618

Fernandez MM, Mordin M, Hadacek MB, Moecklinghoff C, Vloeberghs E, El khoury A, Tronczynski K. PrEP reimbursement and access in Europe: 2019 update. Poster presented at the 17th European AIDS Conference; November 2019. Basel, Switzerland. [abstract] HIV Med. 2019 Nov 6; 20(Suppl. 9):240. doi: 10.1111/hiv.12814

Brogan AJ, Talbird SE, Davis AE, Wild L, Flanagan D. Is increased screening and early antiretroviral treatment for HIV-1 worth the investment? An analysis of the public health and economic impact of improvement in the UK. HIV Med. 2019 Nov;20(10):668-80. doi: 10.1111/hiv.12788

Wasserman M, Lucas A, Jones D, Wilson M, Hilton B, Vyse A, Madhava H, Brogan A. Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK. Epidemiol Infect. 2018 Oct;146(14):1797-806. doi: 10.1017/S095026881800198X

Buck PO, Meyers JL, Gordon LD, Parikh R, Kurosky SK, Davis KL. Economic burden of diagnosed pertussis among individuals with asthma or chronic obstructive pulmonary disease in the USA: an analysis of administrative claims. Epidemiol Infect. 2017 Jul;145(10):2109-21. doi: 10.1017/S0950268817000887.

Wilkins E, Fisher M, Brogan AJ, Talbird SE, La EM. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial. HIV Med. 2016 Aug;17(7):505-15. doi: 10.1111/hiv.12349

Jimenez-Murcia S, Granero R, Larrea ST, Sauvaget A, Grall-Bronnec M, Alvarez-Moya EM, Aguera Z, Aymami N, Gomez-Pena M, Del Pino-Gutierrez A, Moragas L, Menchon JM, Fagundo AB, Sauchelli S, La Verde M, Aguglia E, Signorelli MS, Formoso JAF, Fernandez-Aranda F. Pathological gambling and substance use disorders: effects of early incidence and personality. Drugs Health Society. 2015 Jan;14(1):78. doi: 10.7202/1035550ar

Mladsi D, Curtis S, Bell MJ, Ito T, Wilson M, Aboud M. Resource utilisation and cost of managing adverse events (AEs) associated with highly active antiretroviral therapy (HAART) in patients with HIV-1. Poster presented at the 18th Annual Conference of the British HIV Association; April 1, 2012. Birmingham, UK. [abstract] HIV Med. 2012 Apr 18; 13(SI):17-8.

Poulos C, Riewpaiboon A, Stewart JF, Clemens J, Guh S, Agtini M, Sur D, Islam Z, Lucas M, Whittington D. Costs of illness due to endemic cholera. Epidemiol Infect. 2012 Mar 1;140(03):500-9.

Richter A, Pladevall M, Manjunath R, Lafata JE, Xi H, Simpkins J, Brar I, Markowitz N, Iloeje U, Irish W. Patient characteristics and costs associated with dyslipidaemia and related conditions in HIV-infected patients: a retrospective cohort study. HIV Med. 2005 Mar 1;6(2):79-90.

Parsley (Edwards) TL. Review of the phantom respondents: opinion surveys and political representation. J Off Stat. 1994;10(3):351-5.